A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Trial Details
- NCT ID
- NCT07198867
- Phase
- PHASE1
- Sponsor
- First Affiliated Hospital of Zhejiang University
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- 18 to 75 years old at the time of signing the Informed Consent Form (ICF)
- More than 12 weeks of expected survival
- ECOG score 0 or 1
- Relapsed or refractory AML
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →